Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director | May 12, 2020 | May 14, 2020 |
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director | May 22, 2019 | May 25, 2019 |
| CODEXIS, INC.CDXS · Entity 6428 | Director | June 17, 2026 | June 18, 2026 |
| IPI Legacy Liquidation CoIMPL · Entity 15659 | Director | June 16, 2022 | June 17, 2022 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 12, 2025 | June 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date May 12, 2020 · Filed May 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2030-05-12 | Direct | 22,000 |
Reported balance
After 2020-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-12 · Grant · Acquired 22,000 · Balance 22,000 F1: The options vest 100% on the earlier of May 12, 2021 or the date immediately prior to the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on the earlier of May 12, 2021 or the date immediately prior to the Issuer's next annual meeting of stockholders.
Armata Pharmaceuticals, Inc.
Report date May 22, 2019 · Filed May 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2029-05-22 | Direct | 27,383 |
Reported balance
After 2019-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-22 · Grant · Acquired 27,383 · Balance 27,383 F1: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant.
CODEXIS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2036-06-17 | Direct | 66,350 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 66,350 · Balance 66,350 F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.
IPI Legacy Liquidation Co
Report date June 16, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2032-06-15 | Direct | 12,789 |
Reported balance
After 2022-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 12,789 · Balance 12,789 F1: The option is 100% vested on June 16, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is 100% vested on June 16, 2023.
SANGAMO THERAPEUTICS, INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,600 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 112,600 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11 | Direct | 50,000 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 21:00 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 66,350 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001610717-26-000273 · form4.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,350 Underlying: Common Stock · 66,350 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001415889-25-017373 · form4-06162025_040613.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-11 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017373 · form4-06162025_040613.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 23:29 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 40,983 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002131 · form4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,583 F1 · shares: The restricted stock units vest as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:27 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 30,120 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001718 · form4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,600 F1 · shares: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:25 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-24-015761 · form4-06062024_080652.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-03 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:25 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015761 · form4-06062024_080652.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 4, 2025 or (b) the day prior to the 2025 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:08 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 34,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000159 · form4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,480 F1 · shares: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:51 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 27,750 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-23-034403 · doc4.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Stock · 27,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:51 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 13,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034403 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the earlier of (a) June 1, 2024 or (b) the day prior to the 2024 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:41 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 37,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-021869 · doc1.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,878 F1 · shares: Restricted Stock. The shares vest as to one third of the shares on each yearly anniversary of the date of grant, provided that the Reporting Person provides continuous services to the Issuer as an employee, consultant, director or officer through each such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 17:02 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 12,789 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001209191-22-037951 · doc4.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,789 Underlying: Common Stock · 12,789 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option is 100% vested on June 16, 2023. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | PurchaseCommon Stock | 5,000 | $3.60 | $17,996.00 |
DisclosureSEC source: 0001209191-22-034036 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,700 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014149 · doc4.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-24 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014149 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,700 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| July 11, 2021 Filed Jul 13, 2021 17:09 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001209191-21-046570 · doc4.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2031-07-10 F1 · derivative.exercise_date: The option is 100% vested on July 11, 2022. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | Conversion5% Convertible Note · Derivative | Not disclosed | $0.00 | $3,637.48 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · derivative · entry 14 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 271 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's Common Stock set forth above upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price). F8 · derivative.exercise_date: The convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's Common Stock set forth above upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price). F8 · derivative.expiration_date: The convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's Common Stock set forth above upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price). Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionSeries C-1 Preferred Stock · Derivative | 143,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · derivative · entry 13 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The shares of the issuer's Series C-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: The shares of the issuer's Series C-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: The shares of the issuer's Series C-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | OtherSeries C-1 Preferred Stock · Derivative | 47,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · derivative · entry 12 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,986 Underlying: Common Stock · 2,886 shares Expires not disclosed F4 · derivative.exercise_price: The shares of the issuer's Series C-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: The shares of the issuer's Series C-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: The shares of the issuer's Series C-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | OtherSeries C-1 Warrant · Derivative | 47,263 | $8.66 | $409,297.58 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · derivative · entry 11 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series C-1 Preferred Stock · 2,886 shares Expires not disclosed F6 · derivative.exercise_price: The warrant has a net exercise provision under which the holder, in lieu of paying the exercise price in cash, surrendered the warrant and received a net number of shares of common stock based on the $15.00 initial public offering price, after deducting the aggregate exercise price. F7 · derivative.exercise_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and expires immediately prior to the closing of the issuer's IPO if not earlier exercised. F7 · derivative.expiration_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and expires immediately prior to the closing of the issuer's IPO if not earlier exercised. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionSeries A-2 Preferred Stock · Derivative | 120,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · derivative · entry 10 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,355 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. F2 · derivative.exercise_date: The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. F2 · derivative.expiration_date: The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | OtherSeries A-2 Preferred Stock · Derivative | 13,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · derivative · entry 9 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,447 Underlying: Common Stock · 840 shares Expires not disclosed F2 · derivative.exercise_price: The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. F2 · derivative.exercise_date: The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. F2 · derivative.expiration_date: The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | OtherSeries A-2 Warrants · Derivative | 13,756 | $8.19 | $112,661.64 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · derivative · entry 8 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series A-2 Preferred Stock · 840 shares Expires not disclosed F6 · derivative.exercise_price: The warrant has a net exercise provision under which the holder, in lieu of paying the exercise price in cash, surrendered the warrant and received a net number of shares of common stock based on the $15.00 initial public offering price, after deducting the aggregate exercise price. F7 · derivative.exercise_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and expires immediately prior to the closing of the issuer's IPO if not earlier exercised. F7 · derivative.expiration_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and expires immediately prior to the closing of the issuer's IPO if not earlier exercised. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionSeries A-1 Preferred Stock · Derivative | 61,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · derivative · entry 7 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the issuer's Series A-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-254999) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: The shares of the issuer's Series A-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-254999) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: The shares of the issuer's Series A-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-254999) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionCommon Stock | 271 | $13.50 | $3,658.50 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · nonDerivative · entry 6 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents the number of shares issued in connection with the conversion of the convertible promissory note reflected in Table II. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | OtherCommon Stock | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · nonDerivative · entry 5 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,756 F3 · shares: Represents the number of shares that were withheld by the issuer in satisfaction of the exercise price of the warrants listed in Table II and does not represent a sale of securities by the reporting person. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionCommon Stock | 8,793 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · nonDerivative · entry 4 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of the issuer's Series C-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | OtherCommon Stock | 458 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · nonDerivative · entry 3 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,629 F3 · shares: Represents the number of shares that were withheld by the issuer in satisfaction of the exercise price of the warrants listed in Table II and does not represent a sale of securities by the reporting person. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionCommon Stock | 7,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · nonDerivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in the IPO pursuant the Registration Statement, and had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:33 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionCommon Stock | 3,732 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029105 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the issuer's Series A-1 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-254999) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 18:01 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | Other5% Convertible Note due 2021 · Derivative | Not disclosed | $0.00 | $3,637.48 |
DisclosureSEC source: 0001209191-21-028364 · doc4.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 271 shares Expires 2021-12-31 F1 · derivative.exercise_price: The convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into the number of shares of the issuer's Common Stock set forth above upon the closing of the issuer's initial public offering (the "IPO") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021. F1 · derivative.exercise_date: The convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into the number of shares of the issuer's Common Stock set forth above upon the closing of the issuer's initial public offering (the "IPO") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:03 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 16,400 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015510 · doc4.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2031-02-24 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:03 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015510 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,200 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · balance_after: Includes 10,000 shares of common stock issuable upon settlement of RSUs subject to Reporting Person's May 18, 2020 RSU grant that will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the Issuer's 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-030959 · doc4.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-17 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030959 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:28 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-034022 · doc4a.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-17 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:28 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034022 · doc4a.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:06 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001209191-20-029150 · doc4.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The options vest 100% on the earlier of May 12, 2021 or the date immediately prior to the Issuer's next annual meeting of stockholders. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 23:55 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | PurchaseCommon Stock | 3,000 | $5.20 | $15,585.00 |
DisclosureSEC source: 0001209191-20-020353 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · balance_after: Includes 2,500 shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date(s). Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001209191-19-036441 · doc4.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036441 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 22, 2019 Filed May 25, 2019 01:30 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 27,383 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001144204-19-028254 · tv522359_4.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,383 Underlying: Common Stock · 27,383 shares Expires 2029-05-22 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant. Read SEC document |
| May 14, 2019 Filed May 15, 2019 20:49 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001209191-19-030057 · doc4.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2029-05-14 F1 · derivative.exercise_date: The options vest 100% on the earlier of May 14, 2020 or the date immediately prior to the Issuer's next annual meeting of stockholders. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 00:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | PurchaseCommon Stock | 2,000 | $9.00 | $18,001.60 |
DisclosureSEC source: 0001209191-18-058823 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · balance_after: Includes 2,500 shares subject to restricted stock units granted on June 11, 2018. The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:58 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001209191-18-051915 · doc4.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: The options vest in monthly installments over one year commencing one month from September 20 2018. Read SEC document |
| September 07, 2018 Filed Sep 7, 2018 21:45 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | PurchaseCommon Stock | 2,000 | $13.52 | $27,040.00 |
DisclosureSEC source: 0001209191-18-050123 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 F1 · balance_after: Includes 2,500 shares subject to restricted stock units granted on June 11, 2018. The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:27 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0001209191-18-037348 · doc4.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-10 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:27 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037348 · doc4.xml · nonDerivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:56 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-047590 · doc4.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-08-01 Read SEC document |
| August 01, 2017 Filed Sep 12, 2017 19:04 UTC Amendment | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-17-052386 · doc4a.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-08-01 F1 · derivative.exercise_price: This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant. All other terms remain the same. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.